ReviewInternational journal of molecular sciences2022
Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Depression, Anxiety and Suicidal Ideation in Prurigo Nodularis: A Systematic Review and Meta-analysis.Acta dermato-venereologica · 2024Pooled it
- Shared Mechanistic Pathways in Bullous Pemphigoid, Chronic Spontaneous Urticaria, Prurigo Nodularis, and Chronic Prurigo of Unknown Origin: Implications for Targeted Therapies.American journal of clinical dermatology · 2026Review
- Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.Dermatology and therapy · 2026Article
- Literature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents.Clinical, cosmetic and investigational dermatology · 2026Review
- The Central Role of Th2 Immune Response in Inflammatory Dermatoses: From Pathogenesis to Targeted Therapies.International journal of molecular sciences · 2025Review
- Dupilumab: an Additional Arrow in the Quiver for Prurigo Nodularis? Data From a Real-Life Setting.Dermatology practical & conceptual · 2025Article
- Prurigo Nodularis in a Patient With Primary B-Cell Immunodeficiency Successfully Treated With Low-Dose Methotrexate: A Case Report.Clinical case reports · 2025Article
- Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients.Postepy dermatologii i alergologii · 2025Article
- Article
- Abrocitinib as a novel therapeutic approach for refractory prurigo nodularis: real-world evidence.Archives of dermatological research · 2025Article
- Effective Treatment of Prurigo Nodularis With Oral Tofacitinib: A Case Report.Clinical case reports · 2025Article
- Current clinical practice of prurigo nodularis in Japan: A cross-sectional web-survey among dermatologists.The Journal of dermatology · 2025Article
- Paradoxical psoriasis after dupilumab treatment of prurigo nodularis treated with adalimumab.JAAD case reports · 2024Article
- Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.Allergy, asthma & immunology research · 2024Article
- Circadian rhythm of cutaneous pruritus.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
- Characterization of Paediatric Prurigo Nodularis: A Multicentre Retrospective, Observational Study.Acta dermato-venereologica · 2024Observational
- The Significant Role of Atopic Skin Diathesis in Prurigo Nodularis.Sisli Etfal Hastanesi tip bulteni · 2024Article
- Diseases from the Spectrum of Dermatitis and Eczema: Can "Omics" Sciences Help with Better Systematics and More Accurate Differential Diagnosis?International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic nodular prurigo (CNPG) is a recalcitrant chronic itchy disorder that affects the quality of life. It can be triggered by multiple etiologies, such as atopic dermatitis, diabetes, and chronic renal diseases. The mechanisms of CNPG are complicated and involved the interaction of the cutaneous, immune, and nervous systems. Diverse immune cells, including eosinophils, neutrophils, T cells, macrophages, and mast cells infiltrated the lesional skin of CNPG, which initiated the inflammatory cytokines and pruritogens release. In addition, the interaction between the immune cells and activated peripheral sensory nerve fibers by neurotransmitters caused neuroinflammation in the skin and intractable itch. This itch-scratch vicious cycle of CNPG results in disease exacerbation. CNPG is difficult to treat with traditional therapies. Recently, great advances have been made in the pathophysiology of both inflammation and pruritus transmission in CNPG. In this review, we summarize the updated mechanisms and novel therapies for CNPG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.